Shengli Wei

Efficacy, safety, and pharmacokinetics of pumecitinib nasal spray for moderate-to-severe seasonal allergic rhinitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Background Seasonal allergic rhinitis (SAR) is a pollen-triggered condition causing nasal inflammation and quality of life impairment. Pumecitinib, a topical Janus kinase (JAK) inhibitor may modulate allergic inflammation. We evaluated the efficacy, safety, and pharmacokinetics o...